Stifel raises Hinge Health stock price target on app growth rebound

Stifel recently increased its price target for Hinge Health Inc (NYSE:HNGE) to $130, up from $115, on Monday while keeping a Buy rating. The company's shares are currently trading at $111.52, only slightly below its 52-week high of $113.48. Over the past six months, Hinge Health's stock price has surged by 152%.

InvestingPro analysis indicates that the stock may be overvalued based on its Fair Value estimate. The firm employs SensorTower data to monitor the Hinge Health app's performance, including monthly active users. September brought the highest downloads in 2026, building on the August rebound and accelerating growth in the third quarter of 2026. However, monthly active users experienced a slight month-over-month decline, which has since moderated.

The resurgence in app downloads followed a period of growth during August. Stifel analyst David Grossman retained the Buy rating and raised the price target accordingly. Investors seeking further insights into Hinge Health's valuation and growth potential can refer to the detailed Pro Research Report, which covers this and over 1,400 other US equities on InvestingPro.

Additional recent updates include Truist Securities raising its price target for Hinge Health to $112 from $85, and BofA Securities initiating coverage with a Buy rating and a price target of $110.